Compare AbCellera Biologics Inc (ABCL) vs JD.Com Inc (JD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs JD.Com Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while JD.Com Inc trades at $27.55 (market cap $36.37B). The key difference: JD.Com Inc is far larger — about 15.5× AbCellera Biologics Inc's market cap, and JD.Com Inc pays a 3.78% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | JD | |
|---|---|---|
Market Cap | $2.35B | $36.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $36.17 |
52-Week Low | $2.78 | $25.19 |
Enterprise Value | $1.99B | $22.53B |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
JD trades at $26.49, down 0.49% on the day, with a bearish technical signal and mixed sentiment. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 show operational strength, but net income margin compression to 1.05% in 2025 raises concerns. The stock appears undervalued with a P/S of 0.2 and P/E of 19.66, while analyst consensus remains strongly bullish with a $39.20 price target.
The outlook is cautiously optimistic given JD's low valuation and consistent earnings outperformance, but risks include legal investigations, margin pressure, and macroeconomic headwinds. Upside potential exists if the company can sustain revenue growth and improve profitability, though near-term volatility may persist due to negative news flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
